Cindy L. O’Bryant

Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G₁ Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2

Jennifer L. Spratlin, Roger B. Cohen, Matthew Eadens et al. · Journal of Clinical Oncology · 2010 · 557 citations · Full text

Medicine, Oncology, Pharmacology +17

A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors

David S. Hong, Daniel W. Bowles, Gerald S. Falchook et al. · Clinical Cancer Research · 2012 · 175 citations

Medicine, Oncology, Pharmacology +15

A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas

Lia Gore, Mace L. Rothenberg, Cindy L. O’Bryant et al. · Clinical Cancer Research · 2008 · 173 citations · Full text

Medicine, Oncology, Pharmacology +12

Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study

Stephen Leong, Roger B. Cohen, Daniel L. Gustafson et al. · Journal of Clinical Oncology · 2009 · 120 citations · Full text

Medicine, Oncology, Pharmacology +17

A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients with Advanced Solid Tumors

M. Basche, Daniel L. Gustafson, Scott N. Holden et al. · Clinical Cancer Research · 2006 · 95 citations

Pharmacy, Pharmacokinetics, Pharmacology +11